Uncovering the molecular pathways that drive resistance to targeted cancer therapies through functional genetics

通过功能遗传学揭示导致对靶向癌症治疗产生耐药性的分子途径

• 批准号: 268796
• 负责人: Huang Sidong
• 金额: $ 21.86万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Salary Programs
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-09-01 至 2017-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=268796&lang=en
• 关键词: Drug Resistance; Genetic Screens; Targeted Cancer Therapy

Clinical trials with targeted cancer therapeutics have demonstrated that the benefit of these agents is frequently limited to small groups of patients. Moreover, this benefit is often limited, due to the rapid development of resistance. Thus, we need biom

靶向癌症治疗的临床试验已经证明，这些药物的益处通常仅限于少数患者。此外，由于耐药性的迅速发展，这种益处往往是有限的。因此，我们需要biom